Neihulizumab (Anti-PSGL1 / CD162) is a humanized, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1, SELPLG, CD162) with potential immunosuppressive activity. It can halt the progression of T-cell-mediated autoimmune diseases and acute graft-versus-host disease (GvHD). MW: 150 kD.